Incretins, such as glucagon‐like peptide‐1 (GLP1) and glucose‐dependent insulinotropic polypeptide (GIP), have advanced the treatment landscape of obesity to a new pinnacle. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.